Member Info for OAPK20

Dodge a company can’t RNS - The skincare and ingestible product ranges will be available to purchase from early December 2021 accompanied by a comprehensive marketing activation, building to a full omni-channel launch at the start of FEBRUARY 2022.

Then say less than 2 months later - A full-scale marketing campaign is expected to commence during the FIRST QUARTER of 2022.

It’s unforgivable. The board can’t expect trust from shareholders when this is the level of communication.
It’s no wonder people are dumping.

The opportunity is there but the way they are going about it is frankly shoddy.
If they RNS February 2022 then they should stick to it. Or is that why the CEO was replaced. If Willow are struggling to meet CBG demand then shareholders should be updated.

11th November RNS - The skincare and ingestible product ranges will be available to purchase from early December 2021 accompanied by a comprehensive marketing activation, building to a full omni-channel launch at the start of FEBRUARY 2022.

AGM today QnA
“How did the December product launch go and what was the customer feedback?

We have had an encouraging response to our soft launch in December though it is too early to draw conclusions. A full-scale marketing campaign is expected to commence during the FIRST QUARTER of 2022. We are particularly pleased with the high customer reviews scores which are currently at 4.5 out of 5. We aim to do even better with high scores by the time our Spring campaign launches! Our top product in December was the Feel Better supplement capsules that received a 5.0-star rating from customers. Interestingly, we also received great feedback from customers who say they have benefitted from improved sleep. The second most loved product was the after-shave balm, which got 4.8. We couldn’t be happier with such positive feedback from our customers.”

Don’t they get $11.4 million once approval is gained in China. Supposed to be during 2022, so hopefully by Q3. If so that may reduce the need for further raise as US sales gain traction. Then there is Norgine who need to improve performane

Someone dumping constantly

NM

Maybe no “incentive” to pump it.

The target review timeline ranging from 7 months (accelerated review and ANDS) to 1 year (standard NDS). The exact time for Health Canada to review drug safety and efficacy information from an NDS depends on the type of drug, the quality of the dossier, the amount of questions that Health Canada raises during the review process, the answers provided by the sponsor and if the targeted timelines for the responses are respected. Once the review is complete, the Regulatory Agency decides to approve (or reject) the use of a new medication. In some instances, it can take longer than the targeted review timelines. HPFB review timelines are based on internationally competitive performance targets that are usually respected. By experience, the review can take anywhere from 6 months to 2 years, rarely more.

Licence Agreement in Canada for Accrufer(R)

Exclusive licence agreement with KYE Pharmaceuticals Inc. fo r development and commercialisation of Accrufer(R)

Deal Highlights:

-- Up to GBP1 million in upfront, development and sales milestones
-- Double-digit royalties on net sales
-- KYE Pharmaceuticals Inc. to be responsible for, and cover costs of all development and regulatory activity

KYE specializes in in-licensing (natural health and prescription drug products), offering expertise in the Canadian landscape from registration through to commercialization and our integrative approach leaves us well-positioned to bring value to our partners, Canadian patients, and Canadian healthcare professionals.

Pict you do know the link between CBX and Haig and DB ?

CBX need to get their finger out and compete with Cannary and CW celeb endorsement as seen on TV ads.

Good timing, it could be suggested. What markets could be available stateside for “a 'movement range' aimed at the after-sports market. We anticipate this will be ready for consumer launch in 2022.”

American Football. Proper Football (Soccer). Ice Hockey. Baseball. Athletics. Winter Olympic sports.
From college to Elite level.
“ According to BDS Analytics and Arcview Market Research, the market for annual CBD sales in the USA will surpass $20 billion by 2024.”
Crucial point “ Similarly, the World Anti Doping Agency has removed CBD from its list of prohibited substances, enabling use by professional and amateur athletes. The World Health Organization has also stated that CBD is "generally well-tolerated with a good safety profile".

Big opportunities over the pond and world wide

VANCOUVER, BC, Nov. 15, 2021 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF) has released its financial and operating results for the three and nine months ended September 30, 2021, reporting significant advancement in its operations and strong liquidity.

With $35.7 million of cash on the Company's balance sheet as at September 30, 2021, favourable regulatory regime changes being discussed in the United States, a first commercial production run completed and first commercial agreement signed, the Company is in a position of strength to execute on its business plan. While the market for biosynthetically produced cannabinoids is new, Willow is at the forefront of this industry and will continue to demonstrate itself as a market leader.

A full description of Willow's third quarter 2020 results can be found in Willow's unaudited condensed consolidated interim financial statements and related management's discussion and analysis which are available on SEDAR at www.sedar.com.

About Willow Biosciences Inc.

Willow is a leading biotechnology company that develops and produces high-purity, plant derived ingredients for the consumer care, food and beverage, and pharmaceutical markets. Willow's biotechnology platform allows creation of a consistent, scalable and sustainable product that benefits both B2B and B2C customers. Willow's R&D team has a proven track record of developing and commercializing bio-based manufacturing processes and products for both the consumer and pharmaceutical industries.

Some people work 40 years in a career to earn a living but some investors think 9 months is a long time let alone 5 years.
Some traders think 9 minutes are an age but each to their own.

Someone trying to get back in lower. Which part wasn’t clear enough ?

“The skincare and ingestible product ranges will be available to purchase from early December 2021 accompanied by a comprehensive marketing activation, building to a full omni-channel launch at the start of February 2022. The timings are in-line with industry best-practice whereby new beauty and wellness products typically go on sale early in the year to coincide with consumers' focus on self-care and forming positive habits, as well as avoiding the hyper competitive pre-Christmas rush where return on ad spend is poor for new entrants.“

Or were they not clear enough here ?

Launch of inaugural product range and ecommerce platform

Cellular Goods (LSE: CBX), a UK-based provider of premium consumer products formulated with lab-made cannabinoids, is pleased to announce the launch today of its inaugural product ranges and ecommerce platform, found at cellulargoods.co.

The launch comprises two product ranges and comes just nine months after the start-up of the Company's commercial operations following its flotation on the London Stock Exchange.

The inaugural range comprises the UK's first premium CBG (cannabigerol) skincare offering including a serum, a face-oil and an after-shaving moisturiser. The products contain ultra-pure, biosynthetic CBG, which has demonstrated anti-inflammatory, anti-oxidant and anti-bacterial properties. All three products have been through an extensive testing process and are fully validated for marketing and labelling as suitable for sensitive skin, dermatologically tested and dermatologist approved.

The second range is a clinically validated CBD (cannabidiol) ingestibles range. This range complies with novel food regulations in both the UK and the EU and is certified under Good Manufacturing Practice (GMP) standards. The ingestibles range comprises a tincture, a spray and capsules, covering the most popular methods of consumption. These have been extensively tested to ensure safety, stability and quality. Both product ranges do not require the cultivation of the cannabis sativa plant, and contain 0% THC, the psychoactive component of cannabis sativa.

In addition, the Company's new ecommerce platform has gone live, enabling customers in the UK to place online purchase orders for five of the six products as of today. The skincare serum will go on sale from February 2022 due to supply constraints at the Company's manufacturing partner until early in the new year.

Last couple of days. Buys or sells

£10

Interesting pricing. Express Scripts doing home delivery at lower price range. InsideRX site offering digital discount card.
If no pre authorisation is required then Dr’s can prescribe without Insurance company authorisation.
Current Covid situation may persuade patients to switch to Accrufer rather than attend hospital for IV.
Now that Express Scripts are on board with home delivery it’s a case of wait and see with patient uptake.

https://insiderx.com/drugs/accrufer/prices

Order numbers are recirculated by companies.

Commercial-Scale Manufacturing for Saori® Soybean Seed Treatment



Plant Health Care® (AIM: PHC.L) a leading provider of novel patent-protected biological products to global agriculture markets, is pleased to provide the following update in relation to the volume manufacture of its Saori soybean seed treatment, recently launched in Brazil with Nutrien Ag Solutions.



Highlights

- Signed a production and supply agreement with a leading European-based fermentation company, securing production capacity of PHC279, the active ingredient in its Saori soybean seed treatment, to meet projected global demand.

- Volume production cost targets have been met, ensuring an attractive gross margin for the Company and an attractive Return on Investment (ROI) for soybean farmers in Brazil.

- Commencing pilot-scale manufacturing of other PREtec peptides within the same facility in support of new product regulatory filings and, ultimately, commercial-scale manufacturing of a portfolio of PREtec-based products.



Overview

Saori, which is proven to make soy plants healthier, improve resistance to disease and increases yield in an environmentally sustainable way, is the Company's first product from its PREtec platform to be commercialised and is the first PREtec peptide approved in Brazil.



PREtec peptides represent a novel class of technology which stimulate the plant to defend itself. Derived from natural proteins, PREtec is an environmentally friendly approach to protecting crops and is compatible with mainstream agricultural practices.



The Company intends to commercialise Saori and other PREtec peptides in markets worth more than $5 billion.

The launch of PHC279 in the USA will follow, once regulatory licences have been obtained, which is anticipated in the second half of 2022.



Chris Richards, CEO of Plant Health Care said, "We are delighted to have achieved this critical milestone in bringing our exciting new technology to market around the world. This new agreement establishes a first-class capability to supply Saori directly to our distribution partner in Brazil. Initial grower response to the launch of the Saori soybean seed treatment with Nutrien Ag Solutions in Brazil has been most encouraging and we are pleased to have established manufacturing arrangements to support wider adoption of PHC279 in 2022 and beyond."

Was it paid back ?

Under the 2018 agreement with Norgine a EUR2.5 million milestone was payable by Norgine to Shield in the event that the H2H study achieved its primary endpoint in the trial protocol. Since it is now clear that the study's primary endpoint was not achieved, we have agreed to repay the milestone to Norgine.